Characteristics and experimental application of polylactic acid copolymer composite sustained-release drug materials

doi:10.3969/j.issn.2095-4344.2013.08.024

Abstract

Abstract:

BACKGROUND: Polylactic acid copolymer composite sustained-release drug materials can reduce the toxic side effects of drugs, extend the action time and improve the effect of the drugs, and it is the hot spot of the drug research recently.
OBJECTIVE: To identify the characteristics and experimental application of various polylactic acid copolymer composite sustained-release drug materials.
METHODS: Different types of drugs were copolymerized with the polylactic acid to form the polylactic acid copolymer composite sustained-release drug materials, and the drug release characteristics and the treatment effect of various polylactic acid copolymer composite sustained-release drug materials in the animal experimental studies were analyzed.
RESULTS AND CONCLUSION: Studies have found that many types of drug can be copolymerized with the polylactic acid and form the polylactic acid copolymer composite sustained-release drug material system, including the anti-tumor drugs, anti-bacterial drugs, anti-viral drugs, anti-tuberculosis drugs, drugs for the prevention and treatment of cardiovascular and cerebrovascular diseases and the metabolic drugs. The drugs above can prolong the action time, effectively stabilize the plasma concentration, obtain the role of targeted therapy and significantly improve the treatment effect after copolymerized with the polylactic acid and form the polylactic acid copolymer composite sustained-release drug material system.

Key words: biomaterials, academic discussion of the biomaterials, drugs, sustained-release, polylactic acid, tumor, glioma, tuberculosis, anti-bacterial, anti-viral, 5-fluorouracil, doxorubicin, epirubicin, paclitaxel, ofloxacin hydrochloride, azithromycin, tinidazole, isoniazid, rifampicin

CLC Number:

R318

Wang Dan, Jiang Hang-hang. Characteristics and experimental application of polylactic acid copolymer composite sustained-release drug materials[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(8): 1473-1480.

Figures/Tables 7

References

[1] Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-1822.

[2] Deitzel JM, Kleinmeyer JD, Hirvonen JK, et al. Controlled deposition of electrospun poly(ethylene oxide) fibers. Polymer. 2000;42:8163-8170.

[3] Zussman E, Burman M, Yarin AL, et al. Tensile deformation of electrospun nylon-6,6 nanofibers. Journal of Polymer Science B: Polymer Physics. 2006;44:1482-1489.

[4] Auras R, Harte B, Selke S. An overview of polylactides as packaging materials. Macromol Biosci. 2004;4(9):835-864.

[5] 石淑先,夏宇正,郭祖鹏,等.聚D，L-乳酸的合成及表征[J].弹性体,2002,12(6):10-13.

[6] Drumright RE, Gruber PR, Henton DE. Polylactic acid technology. Advanced Materials. 2000;12:1841-1846.

[7] Pelouze J. Memoire sure l'acide lactique. Annual Chimie. 1845;3(13):257-268.

[8] Carothers WH, Dorough GL, Van Natta FJ. Studies of polymerization and ring formation. X. The reversible polymerization of six-membered cyclic ester. Journal of the American Chemical Society. 1932;54:761-772.

[9] Lowe CE. Preparation of high molecular weight polyhydroxyacetic ester. US Patent, 2668162,1954.

[10] Yolles S, Leaffe T, Ward L, et al. Controlled release of biologically active drugs. Bull Parenter Drug Assoc. 1976; 30(6):306-312.

[11] Uchida T, Yoshida K, Ninomiya A, et al. Optimization of preparative conditions for polylactide (PLA) microspheres containing ovalbumin. Chem Pharm Bull (Tokyo). 1995;43(9): 1569-1573.

[12] Cao X, Schoichet MS. Delivering neuroactive molecules from biodegradable microspheres for application in central nervous system disorders. Biomaterials. 1999;20(4):329-339.

[13] 郭圣荣.医药用生物降解性高分子材料[M].北京：化学工业出版社,2003.42-43.

[14] 中国知网.中国学术期刊总库[DB/OL].2012-11-28. https://www.cnki.net

[15] 冯芳.5-FU载药纳米微粒的制备、表征及体外实验[D].甘肃：兰州大学,2009:1-46.

[16] 毕秀增,潘伟华,南开辉,等.5-氟尿嘧啶缓释剂制备及体外释药性能比较[J].中国组织工程研究,2012,16(8):1430-1434.

[17] 周志敏.抗肿瘤药物表阿霉素缓释制剂及聚乳酸自组装行为的研究[D].福建：厦门大学,2006:1-82.

[18] 蔡敏娴,陈志奎,林礼务,等.载多烯紫杉醇聚乳酸-羟基乙酸微球的制备、表征及其药物稳定性[J].中国组织工程研究与临床康复,2010,14(21):3856-3860.

[19] 叶社房,侯振清,周志敏,等.植入型表阿霉素缓释药膜的制备及体内抑瘤活性[J].中国生物医学工程学报,2008,27(4): 586-590.

[20] 刘杰,徐伟华,金成,等.载阿霉素PLGA纳米微球的制备及性质研究[J].现代生物医学进展,2010,10(24):4661-4663.

[21] 胡庆军.聚DL-乳酸在HA复合材料与药物缓释中的应用[D].湖北：华中科技大学,2006:1-59.

[22] 刘娟,肖丽英,李伟,等.可吸收聚乳酸-替硝唑抗菌缓释剂体外药物释放效果的测定[J].华西口腔医学杂志,2005,23(3):237-239.

[23] 王哲,张秀梅,倪宏哲,等.聚乳酸载阿奇霉素微球包裹和体外释放行为[J].中国生物医学工程学报,2009,28(2):314-316.

[24] 刘江涛,王永清,夏侃,等.异烟肼聚乳酸缓释体的制备及体内外释药特性[J].中国脊柱脊髓杂志,2008,18(4):290-293.

[25] 叶向阳,孙湘,贾会文,等.利福平/聚乳酸-聚羟基乙酸缓释微球的制备及特性[J].中国组织工程研究与临床康复,2011,15(51): 9608-9612.

[26] 胡春晖.利福平微球-原位凝胶复合缓释载体的研究[D].北京：北京协和医学院,2011:1-109.

[27] 肖莉,张韵慧,崔颖,等.尼莫地平聚乳酸缓释微球的制备及其药剂学性质[J].中国医院药学杂志,2008,28(3):194-198.

[28] 刘国磊,王帅,王静,等.长春西汀聚乳酸-聚乙醇酸缓释微球的研制[J].中国药房,2012,23(13):1203-1206.

[29] 张敏.洛伐他汀聚乳酸微球的制备及释药特性[D].北京：北京化工大学,2011:1-89.

[30] 胡婧.羟基喜树碱缓释片脑内植入治疗脑胶质瘤的研究[D].重庆：第三军医大学,2008:1-68.

[31] 索新,刘伟,郭永川,等.可生物降解高分子超细纤维PLA药物缓释体作用于脑胶质瘤的体外研究[J].中国微侵袭神经外科杂志, 2006, 11(12):558-561.

[32] Asmus LR, Tille JC, Kaufmann B, et al. In vivo biocompatibility, sustained-release and stability of triptorelin formulations based on a liquid, degradable polymer. J Control Release. 2012;165(3):199-206.

[33] Ranjan AP, Mukerjee A, Helson L, et al. Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy. J Nanobiotechnology. 2012; 10:38.

[34] Asmus LR, Kaufmann B, Melander L, et al. Single processing step toward injectable sustained-release formulations of Triptorelin based on a novel degradable semi-solid polymer. Eur J Pharm Biopharm. 2012;81(3):591-599.

[35] Agrawal R, Shanavas A, Yadav S, et al. Polyelectrolyte coated polymeric nanoparticles for controlled release of docetaxel. J Biomed Nanotechnol. 2012;8(1):19-28.

[36] Parker T, Davé V, Falotico R, et al. Control of cilostazol release kinetics and direction from a stent using a reservoir-based design. J Biomed Mater Res B Appl Biomater. 2012;100(3):603-610.

[37] Asmus LR, Gurny R, Möller M. Solutions as solutions--synthesis and use of a liquid polyester excipient to dissolve lipophilic drugs and formulatesustained-release parenterals. Eur J Pharm Biopharm. 2011;79(3):584-591.

[38] Zhan W, Zhang X. Preparation of sustained release microspheres containing extracts from Caulis sinomenii with polylactic acid and their release property in vitro. Zhongguo Zhong Yao Za Zhi. 2010;35(16):2142-2145.

[39] Wang TW, Wu Y, Li MJ, et al. Preparation and drug release property of paclitaxel nanoparticles. Zhong Yao Cai. 2009; 32(9): 1447-1449.

[40] Kang C, Yuan X, Zhong Y, et al. Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D,L-lactic acid) nanoparticles. Technol Cancer Res Treat. 2009;8(1):61-70.

[41] Gao H, Ping Q, Gu Y. Fabrication, characterization and drug release characteristics of drug loaded poly (L-lactic acid) fiber. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2008;25(4): 870-873.

[42] Rothen-Weinhold A, Besseghir K, Vuaridel E, et al. Injection-molding versus extrusion as manufacturing technique for the preparation of biodegradable implants. Eur J Pharm Biopharm. 1999;48(2):113-121.

[43] Pardridge WM. Drug targeting to the brain. Pharm Res. 2007; 24(9):1733-1744.

[44] Mariette B, Coudane J, Vert M. Interactions of GRF(1-29)NH2 with plasma proteins and their effects on the release of the peptide from a PLAGA matrix. J Control Release. 2005;106(3): 253-262.

[45] Yamagata T, Morishita M, Kavimandan NJ, et al. Characterization of insulin protection properties of complexation hydrogels in gastric and intestinal enzyme fluids. J Control Release. 2006;112(3):343-349.

[46] Edelman ER, Langer R. Optimization of release from magnetically controlled polymeric drug release devices. Biomaterials. 1993;14(8):621-626.